A study on combination therapy targeting activated ERBB2 and PIK3CA mutations in cervical cancer found that the majority of cervical tumors could benefit from existing ERBB2/PIK3CA/AKT/mTOR-targeted drugs [36]. This evidence concerns the gene PIK3CA and cervical carcinoma.